Biotechnology News 16 October 2025 - 20 October 2025

Beam Stock Rallies on Technical Breakout Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping

Stock Soars on Positive Trial News Celcuity’s stock price skyrocketed on October 20, 2025 after the Minneapolis-based biotech reported game-changing clinical trial results. Shares jumped from around $52 to as high as $78–$81 intradaymarketbeat.com, an approximately 40–50% single-day leap, before settling near a record high close. This surge marked a new 52-week high of $81.56marketbeat.com and lifted Celcuity’s market capitalization above $2.2 billioninvesting.com. The stunning rally came on unusually heavy trading volume as investors rushed to buy shares, propelled by news from a major cancer conference. The immediate catalyst was Celcuity’s Phase 3 VIKTORIA-1 trial data presented over the weekend at

Key Facts – October 18, 2025 MNMD Stock Rallies to New Highs on Heavy Volume MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 on unusually heavy volumets2.tech. After a brief mid-week pullback on profit-taking (shares dipped ~4% intraday on Oct. 16)ts2.tech, MNMD roared back by week’s end – closing at $13.65 on Friday, Oct. 17, a one-day gain of +14.6%investing.com. This rally has propelled MindMed to roughly +68% YTD returnsts2.tech, a remarkable run fueled by excitement over the

FDA Setback Triggers Strategic Review Kezar Life Sciences revealed a major regulatory setback for its lead drug and immediately pivoted to consider strategic alternatives. In an October 16 press release, the South San Francisco company announced it failed to reach alignment with the U.S. Food and Drug Administration on the design of a pivotal trial for zetomipzomib in autoimmune hepatitis (AIH)ca.investing.com. The FDA abruptly canceled a Type C meeting that was scheduled for Q4 2025 to discuss Kezar’s proposed Phase 3 trial, and instead requested a new standalone study to characterize zetomipzomib’s pharmacokinetics in patients with severe liver impairmentstocktitan.netstocktitan.net. The

Samsung Partnership Sparks Stock Surge GRAIL, Inc. (NASDAQ: GRAL) shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per sharets2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singaporets2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technologytradingview.comprnewswire.com. Investors cheered the deal as a major

Stock Rebounds on Moderna’s “Make-or-Break” Week Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once